Netherlands· NL-fb6d1479d06e
Terazosine Accord 1 mg tabletten
A terazosin product containing terazosinehydrochloride 2-water, registered in Netherlands by Accord Healthcare B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Terazosin is registered in 12 of 19 countries.
Countries holding a registration under ATC G04CA03 (terazosin), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 7 of them publish a price we can compare per daily dose
Terazosin · ATC G04CA03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of terazosin costs, country by country.
Normalised to the WHO defined daily dose (5 mg), the median price runs from $0.19 in United States to $0.93 in Switzerland — a ×5.0 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Terazosin · price per daily dose (5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.93
- IT Italy$0.31
- US United States$0.19 (acquisition cost)
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- TERAZOSINEHYDROCHLORIDE 2-WATER
- Manufacturer
- Accord Healthcare B.V.
- Country
- Netherlands (NL)
- ATC code
- G04CA03
- ATC class
- Terazosin
- Defined daily dose
- 5 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_id100579
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
186 interactions on record for terazosin.
Graded by severity as the source publishes them — 72 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Terazosin · interactions on record
186 records
- 72 moderate
- 1 minor
- 112 info
Most severe, free to view
- ThiethylperazinA04AB03moderate
- DiphenhydraminA04AB05moderate
- DronabinolA04AD10moderate
- NabiloneA04AD11moderate
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Terazosin in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaAPO-TERAZOSINAPOTEX INC
- FranceDYSALFA 1 mg, compriméAMDIPHARM
- SwitzerlandHytrin BPH Starterpackung
- United KingdomHytrin 1mg tabletsAdvanz Pharma
- SwedenSinalfa 1 mg + 2 mg TablettAmdipharm Limited
- United StatesterazosinREMEDYREPACK INC.
- ItalyITRINEBERLIFE FARMACEUTICI S.P.A.
- BelgiumHytrin 1 mgAmdipharm
Authorised across Europe · EMA
The same active substance is authorised in 19 EEA countries. Names it is sold under:
- Austria · Uroflo, Vicard
- Belgium · Hytrin, Terazosab
- Czechia · Kornam
- Germany · Heitrin, Tera Tad
- Denmark · Sinalfa
- Spain · Alfaprost, Mayul
- France · Dysalfa, Hytrine
- United Kingdom (Northern Ireland) · Hytrin, Terazosin
- Greece · Hytrin
- Hungary · Setegis
- Ireland · Hytrin
- Italy · Itrin, Prostatil
- Luxembourg · Hytrin, Terazosab
- Norway · Sinalfa
- Poland · Hytrin, Kornam
- Portugal · Hytrin
- Sweden · Sinalfa
- Slovenia · Kornam
- Slovakia · Kornam
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c4aee227-25f0-4a54-9f28-7bdefa4c2d6d GET /v1/drugs/c4aee227-25f0-4a54-9f28-7bdefa4c2d6d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"route": "Oraal gebruik",
"soort": "RVG",
"source": "cbg_meb",
"smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h100579_smpc.pdf",
"strength": null,
"atc_label": "Terazosin",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg100579",
"excipients": [
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"MAÏSZETMEEL",
"TALK (E 553b)"
],
"substances": [
"TERAZOSINEHYDROCHLORIDE 2-WATER"
],
"leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h100579.pdf",
"authorised_at": "2009/09/21",
"procedure_number": "NL/H/1161/001",
"dispensing_status": "Uitsluitend recept",
"registration_number": "100579",
"additional_monitoring": "N"
}See everything about terazosin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.